New Regulations Effective Today Aim to Cut Setup Times and Boost UK's Life Sciences Sector
The most significant overhaul of UK clinical trial regulations in twenty years came into force today, Tuesday 28 April, with new rules from the Medicines and Healthcare products Regulatory Agency and the Health Research Authority designed to slash approval times, increase transparency, and cement Britain's position as a global destination for medical research — changes that could accelerate access to life-saving treatments for thousands of patients.
Background
Clinical trials are the engine of modern medicine. Without them, new treatments cannot be approved, and patients cannot access the innovations that researchers develop. Yet for years, the UK's clinical trial system has been criticised for being slow, bureaucratic, and out of step with international competitors. The average time to set up a clinical trial in the UK stood at 169 days before recent reforms began to take effect — a figure that placed Britain at a disadvantage compared to the United States and several European nations.
The reforms that come into force today were shaped by a public consultation in 2022 and approved by Westminster Parliament and the House of Lords in February 2025, with the Northern Ireland Assembly giving its approval in April 2025. They represent the culmination of a three-year process involving the MHRA, the HRA, researchers, pharmaceutical companies, patient groups, and NHS trusts across the country. The government's ambition, set out by the Prime Minister in April 2025, was to reduce clinical trial setup times to 150 days by March 2026 — a target the HRA has been working towards through its combined review process, which has already cut average setup times from 169 days to 122 days.
The reforms are also aligned with the government's 10-year plan for the NHS, which sets out an ambition to make Britain one of the best places in the world to conduct clinical research. The life sciences sector contributes approximately £94 billion to the UK economy annually and employs around 300,000 people — making it one of the most strategically important industries in the country.
Key Developments
The new regulations introduce several significant changes. For the first time in the UK, it will be a legal requirement to register clinical trials involving medicines in a public registry and to publish a summary of results within 12 months of completion — a transparency measure that patient groups have long demanded. Sponsors will also be required to offer participants a summary of results in an accessible format.
A new fast-track "Route B" pathway for substantial modifications to ongoing trials — successfully piloted between October 2025 and March 2026 — will now be legally mandated. During the pilot, applications were processed in an average of seven calendar days, compared to weeks under the previous system. A new category of "notifiable trials" is also introduced for lower-risk studies using authorised medicines, which will not require MHRA assessment, reducing the regulatory burden for straightforward research.
Health Innovation and Safety Minister Dr Zubir Ahmed described the reforms as a "landmark moment" for patients, researchers, and the life sciences sector. The HRA has published comprehensive guidance to help researchers and sponsors navigate the new system, and the MHRA has developed a dedicated Clinical Trials Hub for ongoing support.
Why It Matters
The practical impact of these reforms could be profound. Faster approval times mean that patients with serious conditions — cancer, rare diseases, neurological disorders — can access experimental treatments sooner. The transparency requirements will also help address a long-standing problem in medical research: the selective publication of results, which distorts the evidence base and can lead to harmful treatments being used or effective ones being overlooked.
For the UK's life sciences sector, the reforms send a clear signal that Britain is open for business. Since Brexit, there have been persistent concerns that pharmaceutical companies would shift their European trial operations to EU member states rather than running parallel processes in the UK. These reforms — combined with the MHRA's increasing divergence from EU regulatory frameworks — represent a deliberate attempt to make the UK a more attractive destination for global research investment. Unlike Ireland, which remains within the EU regulatory framework, the UK now has the flexibility to move faster and take a more risk-proportionate approach. Whether that flexibility translates into competitive advantage will depend on how effectively the new system is implemented.
Local Impact
For patients and researchers across the UK and Ireland, the reforms have immediate practical implications. NHS trusts in Northern Ireland — including the Belfast Health and Social Care Trust and the Western Health and Social Care Trust — will benefit from faster approval processes for trials they host. For patients in rural areas of Scotland, Wales, and Northern Ireland, the new provisions for decentralised trials — which allow home-based activities and mobile research units — could make participation in clinical research accessible for the first time. The new transparency requirements will also give patients and their families better information about the trials available to them and the results of research that has already been completed.
What's Next
The MHRA and HRA will monitor the implementation of the new regulations closely over the coming months, with a formal review expected in 2027. Researchers and sponsors have a 12-month transition period for some elements of the new framework. The government's target of reducing setup times to 150 days will be assessed against data collected over the next year. Watch also for the publication of the first mandatory trial registrations and results summaries under the new transparency requirements, which will begin to appear in public registries from today.
Sources: GOV.UK, Health Research Authority
